Constitutive Canonical NF-κB Activation Cooperates with Disruption of BLIMP1 in the Pathogenesis of Activated B Cell-like Diffuse Large Cell Lymphoma

Cancer Cell

Volumn 18, Issue 6, 2010, Pages 580-589

  Calado, Dinis Pedro ^a   Zhang, Baochun ^a   Srinivasan, Lakshmi ^a   Sasaki, Yoshiteru ^a,d   Seagal, Jane ^a   Unitt, Christine ^b   Rodig, Scott ^b   Kutok, Jeffery ^b   Tarakhovsky, Alexander ^c   Schmidt Supprian, Marc ^a,e   Rajewsky, Klaus ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

^d RIKEN Center for Biosystems Dynamics Research   (Japan)

^e MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE ACTIVATION; CLONOGENIC ASSAY; CONTROLLED STUDY; DNA CONTENT; GENE DELETION; LARGE CELL LYMPHOMA; LOSS OF FUNCTION MUTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 78650023995     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2010.11.024     Document Type: Article

References (37)

1. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., Boldrick J.C., Sabet H., Tran T., Yu X., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
2. Angelin-Duclos C., Cattoretti G., Lin K.I., Calame K. Commitment of B lymphocytes to a plasma cell fate is associated with Blimp-1 expression in vivo. J. Immunol. 2000, 165:5462-5471.
3. Annunziata C.M., Davis R.E., Demchenko Y., Bellamy W., Gabrea A., Zhan F., Lenz G., Hanamura I., Wright G., Xiao W., et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007, 12:115-130.
4. Banham A.H., Connors J.M., Brown P.J., Cordell J.L., Ott G., Sreenivasan G., Farinha P., Horsman D.E., Gascoyne R.D. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin. Cancer Res. 2005, 11:1065-1072.
5. Bolduc A., Long E., Stapler D., Cascalho M., Tsubata T., Koni P.A., Shimoda M. Constitutive CD40L expression on B cells prematurely terminates germinal center response and leads to augmented plasma cell production in T cell areas. J. Immunol. 2010, 185:220-230.
6. Casola S., Cattoretti G., Uyttersprot N., Koralov S.B., Seagal J., Hao Z., Waisman A., Egert A., Ghitza D., Rajewsky K. Tracking germinal center B cells expressing germ-line immunoglobulin gamma1 transcripts by conditional gene targeting. Proc. Natl. Acad. Sci. USA 2006, 103:7396-7401.
7. Choi W.W., Weisenburger D.D., Greiner T.C., Piris M.A., Banham A.H., Delabie J., Braziel R.M., Geng H., Iqbal J., Lenz G., et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin. Cancer Res. 2009, 15:5494-5502.
8. Compagno M., Lim W.K., Grunn A., Nandula S.V., Brahmachary M., Shen Q., Bertoni F., Ponzoni M., Scandurra M., Califano A., et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009, 459:717-721.
9. Davis R.E., Brown K.D., Siebenlist U., Staudt L.M. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J. Exp. Med. 2001, 194:1861-1874.
10. Davis R.E., Ngo V.N., Lenz G., Tolar P., Young R.M., Romesser P.B., Kohlhammer H., Lamy L., Zhao H., Yang Y., et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010, 463:88-92.
11. Ehlich A., Martin V., Muller W., Rajewsky K. Analysis of the B-cell progenitor compartment at the level of single cells. Curr. Biol. 1994, 4:573-583.
12. Garside P., Ingulli E., Merica R.R., Johnson J.G., Noelle R.J., Jenkins M.K. Visualization of specific B and T lymphocyte interactions in the lymph node. Science 1998, 281:96-99.
13. Grumont R.J., Gerondakis S. Rel induces interferon regulatory factor 4 (IRF-4) expression in lymphocytes: modulation of interferon-regulated gene expression by rel/nuclear factor kappaB. J. Exp. Med. 2000, 191:1281-1292.
14. Hans C.P., Weisenburger D.D., Greiner T.C., Gascoyne R.D., Delabie J., Ott G., Muller-Hermelink H.K., Campo E., Braziel R.M., Jaffe E.S., et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004, 103:275-282.
15. Iqbal J., Greiner T.C., Patel K., Dave B.J., Smith L., Ji J., Wright G., Sanger W.G., Pickering D.L., Jain S., et al. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia 2007, 21:2332-2343.
16. Kato M., Sanada M., Kato I., Sato Y., Takita J., Takeuchi K., Niwa A., Chen Y., Nakazaki K., Nomoto J., et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 2009, 459:712-716.
17. Keats J.J., Fonseca R., Chesi M., Schop R., Baker A., Chng W.J., Van Wier S., Tiedemann R., Shi C.X., Sebag M., et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007, 12:131-144.
18. Kishi Y., Aiba Y., Higuchi T., Furukawa K., Tokuhisa T., Takemori T., Tsubata T. Augmented antibody response with premature germinal center regression in CD40L transgenic mice. J. Immunol. 2010, 185:211-219.
19. Lenz G., Staudt L.M. Aggressive lymphomas. N. Engl. J. Med. 2010, 362:1417-1429.
20. Lenz G., Davis R.E., Ngo V.N., Lam L., George T.C., Wright G.W., Dave S.S., Zhao H., Xu W., Rosenwald A., et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008, 319:1676-1679.
21. Lenz G., Wright G.W., Emre N.C., Kohlhammer H., Dave S.S., Davis R.E., Carty S., Lam L.T., Shaffer A.L., Xiao W., et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc. Natl. Acad. Sci. USA 2008, 105:13520-13525.
22. Lin Y., Wong K., Calame K. Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation. Science 1997, 276:596-599.
23. Lossos I.S., Alizadeh A.A., Eisen M.B., Chan W.C., Brown P.O., Botstein D., Staudt L.M., Levy R. Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proc. Natl. Acad. Sci. USA 2000, 97:10209-10213.
24. Mandelbaum J., Bhagat G., Tang F., Mo T., Brahmachary M., Shen Q., Chadburn A., Rajewsky K., Tarakhovsky A., Pasqualucci L., Dalla-Favera R. BLIMP1/PRDM1 is a tumor suppressor gene frequently disrupted in activated B-cell like diffuse large B cell lymphoma. Cancer Cell 2010, 18:568-579. this issue.
25. Martins G., Calame K. Regulation and functions of Blimp-1 in T and B lymphocytes. Annu. Rev. Immunol. 2008, 26:133-169.
26. Monti S., Savage K.J., Kutok J.L., Feuerhake F., Kurtin P., Mihm M., Wu B., Pasqualucci L., Neuberg D., Aguiar R.C., et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005, 105:1851-1861.
27. Ohinata Y., Payer B., O'Carroll D., Ancelin K., Ono Y., Sano M., Barton S.C., Obukhanych T., Nussenzweig M., Tarakhovsky A., et al. Blimp1 is a critical determinant of the germ cell lineage in mice. Nature 2005, 436:207-213.
28. Pasqualucci L., Compagno M., Houldsworth J., Monti S., Grunn A., Nandula S.V., Aster J.C., Murty V.V., Shipp M.A., Dalla-Favera R. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J. Exp. Med. 2006, 203:311-317.
29. Pavlidis P., Noble W.S. Matrix2png: a utility for visualizing matrix data. Bioinformatics 2003, 19:295-296.
30. Saito M., Gao J., Basso K., Kitagawa Y., Smith P.M., Bhagat G., Pernis A., Pasqualucci L., Dalla-Favera R. A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell 2007, 12:280-292.
31. Sasaki Y., Derudder E., Hobeika E., Pelanda R., Reth M., Rajewsky K., Schmidt-Supprian M. Canonical NF-kappaB activity, dispensable for B cell development, replaces BAFF-receptor signals and promotes B cell proliferation upon activation. Immunity 2006, 24:729-739.
32. Srinivas S., Watanabe T., Lin C.S., William C.M., Tanabe Y., Jessell T.M., Costantini F. Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev. Biol. 2001, 1:4.
33. Staudt L.M. Oncogenic activation of NF-kappaB. Cold Spring Harb. Perspect. Biol. 2010, 2:a000109.
34. Tam W., Gomez M., Chadburn A., Lee J.W., Chan W.C., Knowles D.M. Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. Blood 2006, 107:4090-4100.
35. Toellner K.M., Gulbranson-Judge A., Taylor D.R., Sze D.M., MacLennan I.C. Immunoglobulin switch transcript production in vivo related to the site and time of antigen-specific B cell activation. J. Exp. Med. 1996, 183:2303-2312.
36. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, WHO, WHO Press, Geneva. Fourth Edition.
37. Wright G., Tan B., Rosenwald A., Hurt E.H., Wiestner A., Staudt L.M. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc. Natl. Acad. Sci. USA 2003, 100:9991-9996.